Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Non-Coding Rnas in Cancer Immunotherapy: A Solution to Overcome Immune Resistance? Publisher



Afra F1 ; Eftekhar SP2 ; Farid AS3 ; Ala M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Student Research Committee, Health Research Center, Babol University of Medical Sciences, Babol, Iran
  3. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Experimental Medicine Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Progress in Molecular Biology and Translational Science Published:2024


Abstract

With the rapid advancement in immunotherapy, cancer immune resistance has become more evident, which demands new treatment approaches to achieve greater efficacy. Non-coding RNAs (ncRNAs) are a heterogeneous group of RNAs that are not translated to proteins but instead regulate different stages of gene expression. Recent studies have increasingly supported the critical role of ncRNAs in immune cell-cancer cell cross-talk, and numerous ncRNAs have been implicated in the immune evasion of cancer cells. Cancer cells take advantage of ncRNAs to modulate several signaling pathways and upregulate the expression of immune checkpoints and anti-inflammatory mediators, thereby dampening the anti-tumor response of M1 macrophages, dendritic cells, cytotoxic T cells, and natural killer cells or potentiating the immunosuppressive properties of M2 macrophages, regulatory T cells, and myeloid-derived suppressive cells. Upregulation of immunosuppressive ncRNAs or downregulation of immunogenic ncNRAs is a major driver of resistance to immune checkpoint inhibitors, cancer vaccines, and other means of cancer immunotherapy, making ncRNAs ideal targets for treatment. In addition, ncRNAs released by cancer cells have been demonstrated to possess prognostic values for patients who undergo cancer immunotherapy. Future clinical trials are urged to consider the potential of ncRNAs in cancer immunotherapy. © 2024
Related Docs
View other Related Docs
1. Recent Progress in the Immunotherapy of Hepatocellular Carcinoma: Non-Coding Rna-Based Immunotherapy May Improve the Outcome, Biomedicine and Pharmacotherapy (2023)
2. Prospect of Exosomal Circular Rnas in Breast Cancer: Presents and Future, Molecular Biology Reports (2022)
3. Noncoding Ribonucleic Acids (Rnas) May Improve Response to Immunotherapy in Pancreatic Cancer, ACS Pharmacology and Translational Science (2024)
4. The Landscape of Exosomal Non-Coding Rnas in Breast Cancer Drug Resistance, Focusing on Underlying Molecular Mechanisms, Frontiers in Pharmacology (2023)
5. The Effects of Exercise on Epigenetic Modifications: Focus on Dna Methylation, Histone Modifications and Non-Coding Rnas, Human Cell (2024)
6. Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways, Annals of Hematology (2024)
7. The Immunobiology of Myeloid-Derived Suppressor Cells in Cancer, Tumor Biology (2016)
8. An Overview of Long Noncoding Rnas: Biology, Functions, Therapeutics, Analysis Methods, and Bioinformatics Tools, Cell Biochemistry and Function (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (3)
Mohammad Ali Mansournia (1)
Other Related Docs
9. Circrna-Associated Cerna Networks (Circcenets) in Chronic Obstructive Pulmonary Disease (Copd), Life Sciences (2024)
10. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
11. Circular Rnas in Tuberculosis: From Mechanism of Action to Potential Diagnostic Biomarker, Microbial Pathogenesis (2023)
12. Critical Role of the Long Non-Coding Rnas (Lncrnas) in Radiotherapy (Rt)-Resistance of Gastrointestinal (Gi) Cancer: Is There a Way to Defeat This Resistance?, Pathology Research and Practice (2024)
13. Exosomal Long Non-Coding Rnas: Novel Molecules in Gastrointestinal Cancers’ Progression and Diagnosis, Frontiers in Oncology (2022)
14. Melatonin Targeting Non-Coding Rnas in Cancer: Focus on Mechanisms and Potential Therapeutic Targets, European Journal of Pharmacology (2023)
15. Current and Future Perspectives of Pd-1/Pdl-1 Blockade in Cancer Immunotherapy, Journal of Immunology Research (2021)
16. Circular Rnas: New Genetic Tools in Melanoma, Biomarkers in Medicine (2020)
17. Prostate Cancer and Noncoding Rnas: A Focus on Mirnas, Lncrnas, and Circrnas, Prostate Cancer: Molecular Events and Therapeutic Modalities (2024)
18. Constructing Mrna, Mirna, Circrna and Lncrna Regulatory Network by Analysis of Microarray Data in Breast Cancer, Gene Reports (2022)
19. A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular Rnas, Frontiers in Cell and Developmental Biology (2020)
20. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
21. Non-Coding Rnas As Potential Therapeutic Targets for Receptor Tyrosine Kinase Signaling in Solid Tumors: Current Status and Future Directions, Cancer Cell International (2024)
22. Sestrin2 in Cancer: A Foe or a Friend?, Biomarker Research (2022)
23. Modulation of Colorectal Tumor Behavior Via Lncrna Tp53tg1-Lipidic Nanosystem, Pharmaceutics (2021)
24. Natural Killer Cell Epigenetic Reprogramming in Tumors and Potential for Cancer Immunotherapy, Epigenomics (2023)
25. Circular Rnas (Circrnas) in Cancer Proliferation: Molecular Interactions and Possible Therapeutic Targets, Non-coding RNA Transcripts In Cancer Therapy: Pre-clinical And Clinical Implications (2023)
26. Long Noncoding Rnas and Exosomal Lncrnas: Classification, and Mechanisms in Breast Cancer Metastasis and Drug Resistance, Oncogene (2020)
27. Exosomes and Non-Coding Rnas: Exploring Their Roles in Human Myocardial Dysfunction, Biomedicine and Pharmacotherapy (2025)
28. Cancer Exosomes and Natural Killer Cells Dysfunction: Biological Roles, Clinical Significance and Implications for Immunotherapy, Molecular Cancer (2022)
29. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
30. Non-Coding Rnas and Brain Tumors: Insights Into Their Roles in Apoptosis, Frontiers in Cell and Developmental Biology (2022)
31. Peaceful Existence of Tumor Cells With Their Non-Malignant Neighbors: The Trade of Tumor Cells With Tumor Micro-Environment, Current Chemical Biology (2020)